Prediction of pelvic tumour coverage by magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) from referral imaging

Diagnostic Value of Combined Detection of Pelvic Ultrasound and Serum LH, FSH, and E2 Levels in Children with Idiopathic Central Precocious Puberty

Objective

To study the diagnostic value of combined detection of pelvic ultrasound and serum LH, FSH, and E2 levels in children with idiopathic central precocious puberty (ICPP).

Methods

30 cases of children with ICPP admitted to our hospital from January 2019 to January 2021 were selected as the experimental group, and 30 healthy people during the same period were selected as the control group. Both groups received pelvic ultrasound and serum LH, FSH, and E2 detection; the two groups were compared in terms of serum indicators, combined diagnosis, specificity, and sensitivity.

Results

There were statistical differences in height, leptin, bone age, and areola diameter between the two groups (p < 0.05). The length of the uterus, the volume of the uterus, the area of the ovary, the volume of the ovary, and the maximum diameter of the follicle in the experimental group were larger than those in the control group (p < 0.05). The endometrial thickness of the experimental group was significantly greater than that of the control group (p < 0.05). The levels of serum LH, FSH, and E2 in the experimental group were significantly higher than those in the control group (p < 0.05). The area of the combined detection was significantly larger than that of the single detection. The combined detection was superior to the single detection with respect to the area, standard error a, asymptotic Sig. B, and asymptotic 95% confidence interval (p < 0.05). The sensitivity of the combined detection was significantly higher than that of the single detection.

Conclusion

The combined detection of pelvic ultrasound and serum LH, FSH, and E2 levels may be a preferred technique for the diagnosis of children with ICPP due to its benefits of high sensitivity and accuracy. It is worthy of clinical promotion and application.

High-intensity focused ultrasound ablation in the treatment of recurrent ovary cancer and metastatic pelvic tumors: a feasibility study

OBJECTIVE

To explore the feasibility of high-intensity focused ultrasound (HIFU) ablation for treating metastatic pelvic tumors and recurrent ovary cancer.

MATERIALS AND METHODS

Eight patients with metastatic pelvic tumors or recurrent ovary cancer were enrolled in this study. Among them, 5 patients had ovarian cancer, 1 had cervical cancer, 1 had endometrial cancer, and 1 had rectal cancer. Six of them received abdominal surgical operation for their primary cancer, no one received radiotherapy. HIFU treatment was performed under conscious sedation. Vital signs were monitored during the procedure, and adverse effects were recorded. Postoperative follow-up was performed to observe pain relief and the improvement of the patient's quality of life.

RESULTS

The median age of the patients was 54 (range: 33-76) years, with a total of 12 lesions. The average volume of the lesions was 238.0 cm³. Six patients completed 12 months follow-up. Postoperative pain relief rate was 60% (3/5), and the quality of life improved in the short term. The main adverse effect of HIFU was pain in the treated area, with the pain score lower than 4, and all of which was self-relieved within 1 day after HIFU treatment. No serious complications such as skin burn, intestinal perforation, and nerve injury occurred.

CONCLUSION

HIFU is feasible for the treatment of metastatic pelvic tumors or recurrent ovary cancer without serious complications. Therefore, HIFU seems a promising treatment for recurrent ovary cancer, metastatic pelvic tumors from cervical cancer, endometrial cancer, and rectal cancer.

Quantitative prediction of the extent of pelvic tumour ablation by magnetic resonance-guided high intensity focused ultrasound

BACKGROUND

Patient suitability for magnetic resonance-guided high intensity focused ultrasound (MRgHIFU) therapy of pelvic tumors is currently assessed by visual estimation of the proportion of tumor that can be reached by the device's focus (coverage). Since it is important to assess whether enough energy reaches the tumor to achieve ablation, a methodology for estimating the proportion of the tumor that can be ablated (treatability) was developed. Predicted treatability was compared against clinically achieved thermal ablation.

METHODS

MR Dixon sequence images of five patients with recurrent gynecological tumors were acquired during their treatment. Acousto-thermal simulations were performed using k-Wave for three exposure points (the deepest and shallowest reachable focal points within the tumor, identified from tumor coverage analysis, and a point halfway in-between) per patient. Interpolation between the resulting simulated ablated tissue volumes was used to estimate the maximum treatable depth and hence, tumor treatability. Predicted treatability was compared both to predicted tumor coverage and to the clinically treated tumor volume. The intended and simulated volumes and positions of ablated tissues were compared.

RESULTS

Predicted treatability was less than coverage by 52% (range: 31-78%) of the tumor volume. Predicted and clinical treatability differed by 9% (range: 1-25%) of tumor volume. Ablated tissue volume and position varied with beam path length through tissue.

CONCLUSION

Tumor coverage overestimated patient suitability for MRgHIFU therapy. Employing patient-specific simulations improved treatability assessment. Patient treatability assessment using simulations is feasible.